|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2100052292 |
|
最近更新日期: Date of Last Refreshed on: |
2021-10-24 01:44:07 |
|
注册时间: Date of Registration: |
2021-10-24 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
藏药“十一味维命胶囊”治疗失眠症临床疗效评价研究 |
|
Public title: |
Evaluation of the clinical effect of Shiyiweiming capsule on insomnia |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
藏药“十一味维命胶囊”治疗失眠症临床疗效评价研究 |
|
Scientific title: |
Evaluation of the clinical effect of Shiyiweiming capsule on insomnia |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
昝占全 |
研究负责人: |
仁青东主 |
|
Applicant: |
ZanZhanquan |
Study leader: |
Renqingdongzhu |
|
申请注册联系人电话: Applicant telephone: |
13139054904 |
研究负责人电话:
Study leader's |
15297189073 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
583169281@qq.com |
研究负责人电子邮件: Study leader's E-mail: |
rqdz@yahoo.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
青海省西宁市生物科技产业园区经三路18号 |
研究负责人通讯地址: |
青海省西宁市城北区宁大路251号 |
|
Applicant address: |
18 Jingsan road, Qinghai Biotechnology Industrial Park, Xining, Qinghai Province |
Study leader's address: |
No. 251, Ningda Road, Chengbei district, Xining, Qinghai Province |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
青海久美藏医院有限公司 |
||
|
Applicant's institution: |
Qinghai Jiumei Tibetan Hospital Co. , Ltd. |
||
|
研究负责人所在单位: |
|
||
|
Affiliation of the Leader: |
|
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
jmzy2020—R002 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
青海久美藏医院有限公司医学伦理委员会 |
||
|
Name of the ethic committee: |
Medical Ethics Committee of Qinghai Jiumei Tibetan Hospital Co. , Ltd. |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2020-07-29 00:00:00 | ||
|
伦理委员会联系人: |
久美彭措 |
||
|
Contact Name of the ethic committee: |
jiumeipengcuo |
||
|
伦理委员会联系地址: |
青海省西宁市生物科技产业园区经三路18号 |
||
|
Contact Address of the ethic committee: |
18 Jingsan road, Qinghai Biotechnology Industrial Park, Xining, Qinghai Province |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
15001106999 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
青海久美藏医院有限公司 |
||||||||||||||||||||||
|
Primary sponsor: |
Qinghai Jiumei Tibetan Hospital Co. , Ltd. |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
青海省西宁市生物科技产业园区经三路18号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
18 Jingsan road, Qinghai Biotechnology Industrial Park, Xining, Qinghai Province |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
企业自筹、政府扶持(后补助) |
||||||||||||||||||||||
|
Source(s) of funding: |
Enterprise self-financing, government support (after subsidies) |
||||||||||||||||||||||
|
研究疾病: |
失眠症 |
||||||||||||||||||||||
|
Target disease: |
Insomnia |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
上市后药物 | ||||||||||||||||||||||
|
Study phase: |
4 |
||||||||||||||||||||||
|
研究设计: |
随机抽样 |
||||||||||||||||||||||
|
Study design: |
Randomly Sampling |
||||||||||||||||||||||
|
研究目的: |
临床疗效再评价 |
||||||||||||||||||||||
|
Objectives of Study: |
Reevaluation of clinical efficacy |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
(1)符合符合ICD-10 失眠症诊断标准; |
||||||||||||||||||||||
|
Inclusion criteria |
(1) meet the ICD-10 diagnostic criteria for insomnia; |
||||||||||||||||||||||
|
排除标准: |
(1)任何干扰试验进程或可能干扰睡眠的生活方式:如最近两周内或试验阶段,会有跨越时区的旅行或倒班(夜班白班倒替)等; |
||||||||||||||||||||||
|
Exclusion criteria: |
(1) any lifestyle that interferes with the trial process or may interfere with sleep: If within the last two weeks or during the trial period, there will be travel or shifts across time zones (night shifts, day shifts) , etc. ; (2) special workers who need to operate machinery during the trial period, such as professional drivers, high-altitude workers and so on; (3) daily regular consumption of excessive tea, coffee drinks. (4) exclusion of insomnia caused by other diseases such as Narcolepsy, respiratory-related sleep disorders; (5) history of cancer, myocardial infarction, heart failure, history of mental disorders, history of Drug Abuse, history of drug addiction in the past year; (6) patients with heart, liver, kidney and respiratory function impairment or other serious diseases, AST or ALT were 1.5 times higher than the upper limit of normal value, serum creatinine was higher than the upper limit of normal value; (7) Hama anxiety scale score was higher than 14 when screening; Hamd Depression scale ≥17 points (8) excluded special population: Allergic Constitution, pregnancy, pregnancy or lactation women, allergic to the drug ingredients; (9) patients who participated in other clinical studies within 3 months; (10) patients with apnea; (11) the patients who took the drug after entering the group could affect the function of waking and sleeping or the evaluation of the drug in the test |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2021-01-01 00:00:00至 To 2023-12-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2021-11-01 00:00:00 至 To 2023-11-30 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
随机化双盲试验设计 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
Design of randomized double-blind trial |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
|
|
Blinding: |
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
不共享 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
No sharing |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
病例记录表 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Case record sheet |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |